Reported 2 days ago
Mizuho Securities has reiterated its Outperform rating on Insmed Inc. (NASDAQ: INSM) and increased the price target from $96 to $110, following promising Phase 2b results for their Treprostinil Palmitil Inhalation Powder (TPIP) aimed at treating pulmonary arterial hypertension. Analyst Graig Suvannavejh expressed strong confidence in TPIP's potential, highlighting its role in enhancing Insmed's growth outlook and long-term value.
Source: YAHOO